Mok and colleagues hypothesized that first-line therapy with the EGFR inhibitor gefitinib would be at least as efficacious as carboplatin–paclitaxel chemotherapy in former smokers and light ...
The reversible TKIs erlotinib and gefitinib, which selectively target EGFR, were shown to improve disease outcomes in non-small-cell lung cancer (NSCLC) patients with EGFR mutations, and this ...
Two EGFR-targeting small-molecule inhibitors, gefitinib (Iressa: AstraZeneca, approved in May 2003) and erlotinib (Tarceva: OSI-Genentech, approved in November 2004) received fast-track approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback